RxDoctor Payments Data

Shakeilah Burns

Family · Akron, OHNPI 1003305855

Payments from drug & device makers

$1,608in general payments, 2019–2025

Across 37 payments — averaging $43.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$558
  • Biohaven Pharmaceuticals, Inc.$348
  • Sanofi-aventis U.S. LLC$157
  • Novo Nordisk$128
  • Teva Pharmaceuticals USA, Inc.$118
  • GSK$108
  • plus $191 from 9 others

What the payments were for

  • Food & beverage$1,608100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,608 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$10,319
Medicare patients
57
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide12$24,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$20,077
EliquisApixaban24$18,708
JardianceEmpagliflozin17$18,611
Albuterol Sulfate HfaAlbuterol Sulfate47$1,911
Levothyroxine Sodium39$654
Fluticasone Propionate26$631
Atorvastatin Calcium84$621
Omeprazole32$423
Gabapentin23$399
Metformin Hcl ErMetformin Hcl20$366
Amlodipine Besylate99$352
Hydroxyzine Hcl14$334
Rosuvastatin Calcium20$278
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav34$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$23$24,89112 claims
GSKTrelegy Ellipta$108$20,07713 claims
PfizerEliquis$14$18,70824 claims
Boehringer IngelheimJardiance$13$18,61117 claims
Almatica Pharma LLCSertraline Hcl$31$4911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →